The importance of CD7 and CD56 antigens in acute leukaemias

Basit Öğe Kaydı
dc.contributor.authorTiftik, N
dc.contributor.authorBolaman, Z
dc.contributor.authorBatun, S
dc.contributor.authorAyyildiz, O
dc.contributor.authorIsikdogan, A
dc.contributor.authorKadikoylu, G
dc.contributor.authorMuftuoglu, E
dc.date.accessioned2024-04-24T17:11:31Z
dc.date.available2024-04-24T17:11:31Z
dc.date.issued2004
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe prognostic significance of immunophenotypical properties of leukaemic cells is well known. However, the biological and clinical significance of CD7 and CD56 antigen expression in acute leukaemias are not clearly established. In patients with acute leukaemias, we identified CD7 and CD56 expression and analysed their associations with markers expressed early in haemopoietic ontogeny and clinical parameters. Among 22 patients with acute leukaemia [12 acute myeloblastic leukaemia (AML), 10 acute lymphoblastic leukaemia (ALL)], we found CD7 positivity in 15 of 22 patients (68%) and CD56 positivity in four patients (18%). CD7 positivity was observed in seven patients (58%) with AML and in eight patients (80%) with ALL. CD56 positivity was observed in three patients (25%) with AML and one patient (10%) with ALL. Lymphadenopathy was present in five patients and associated with hepatosplenomegaly in three patients with ALL. Splenomegaly and hepatomegaly were present in three patients with AML. Central nervous system involvement was seen in one patient with ALL. Complete remission was achieved in nine patients (41%) (five ALL and four AML). Our data showed that CD7 and CD56 positivity at diagnosis associated with low remission rate and biological aggressiveness in a significant proportion of patients. We suggest the evaluation of CD7 and CD56 in all patients with acute leukaemias at the time of diagnosis in view of poor clinical outcome.en_US
dc.identifier.doi10.1111/j.1368-5031.2004.0018.x
dc.identifier.endpage152en_US
dc.identifier.issn1368-5031
dc.identifier.issn1742-1241
dc.identifier.issue2en_US
dc.identifier.pmid15055863
dc.identifier.scopus2-s2.0-1842538559
dc.identifier.scopusqualityQ1
dc.identifier.startpage149en_US
dc.identifier.urihttps://doi.org/10.1111/j.1368-5031.2004.0018.x
dc.identifier.urihttps://hdl.handle.net/11468/17573
dc.identifier.volume58en_US
dc.identifier.wosWOS:000220454300009
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal of Clinical Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCd7en_US
dc.subjectCd56en_US
dc.subjectAcute Leukaemiaen_US
dc.titleThe importance of CD7 and CD56 antigens in acute leukaemiasen_US
dc.titleThe importance of CD7 and CD56 antigens in acute leukaemias
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu